Risk of CNS relapse following pathological complete response to neoadjuvant chemotherapy in early breast cancer - PubMed
4 hours ago
- #neoadjuvant chemotherapy
- #breast cancer
- #CNS relapse
- Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) does not necessarily prevent brain metastases in early-stage breast cancer (BC).
- The study analyzed 1147 stage I-III BC patients treated with NAC and surgery, focusing on CNS recurrence patterns by BC subtypes (HR-positive/HER2-negative, HER2-positive, TNBC).
- CNS recurrence occurred in 6.2% of patients, with no significant difference between pCR and non-pCR groups overall, but pCR reduced CNS recurrence risk in HER2-positive BC.
- Isolated CNS relapse was the most common pattern (82.4%) in pCR patients, especially in HER2-positive cases.
- Median overall survival after CNS relapse was 12 months.
- HER2-positive, TNBC, and cN2-3 status were identified as independent predictors of CNS recurrence.